Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin lambda variable 3-26 (IGLV3-26) is a pseudogene within the immunoglobulin lambda variable region gene family. In general, immunoglobulin variable genes encode the variable domains of light chains in antibodies, contributing to the antigen-binding diversity of the immune response. However, IGLV3-26 specifically is classified as a pseudogene, meaning that it does not produce a functional protein and is not involved in encoding functional antibody chains. It is located within the immunoglobulin lambda locus and is part of the broader immunoglobulin (antibody) gene complex, which undergoes somatic rearrangement to produce the antigen-binding diversity essential for adaptive immunity. Because IGLV3-26 is a pseudogene and not known to be expressed as a functional protein, it is not considered a drug target, receptor, enzyme, or direct participant in disease processes[1][2][5][7]. Key points: - The official gene symbol is IGLV3-26. - It is a pseudogene, so it is not expressed as a functional protein[5]. - While functional immunoglobulin lambda variable genes play a role in immune defense, a pseudogene like IGLV3-26 does not encode a protein and therefore is not considered a therapeutic target or biomarker. - There are no known drugs, mechanisms of action, or clinical safety concerns associated with this pseudogene. - Alternative names found include IGLV326 and V2-18P[2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin lambda variable 3-26 (pseudogene) (IGLV3-26).